Home › Multiple Myeloma › North Carolina › Durham
Pag-aaral pangklinika para sa Multiple Myeloma sa Durham, NC
Isang pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Durham. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Nagre-recruitPhase 3
- Research Site, Chapel Hill · 10 mi ang layo
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Nagre-recruitPhase 3
- Durham VAMC, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 mi ang layo
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Nagre-recruitPhase 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- Duke University Medical Center, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Nagre-recruitPhase 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 mi ang layo
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Nagre-recruitPhase 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Nagre-recruitPhase 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 2
- University of North Carolina Medical Center, Chapel Hill · 10 mi ang layo
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Nagre-recruitPhase 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 mi ang layo
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Nagre-recruitPhase 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi ang layo
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Nagre-recruitPhase 1/2
- GSK Investigational Site, Chapel Hill · 10 mi ang layo
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Nagre-recruitPhase 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Nagre-recruitPhase 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 mi ang layo
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Nagre-recruit
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi ang layo
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Nagre-recruitPhase 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Nagre-recruitPhase 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 mi ang layo
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Nagre-recruitPhase 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 mi ang layo
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Nagre-recruitPhase 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 mi ang layo
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Nagre-recruitPhase 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi ang layo
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Nagre-recruitPhase 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mi ang layo
Registry of Older Patients With Cancer
Nagre-recruitObservasyonal na pag-aaral
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi ang layo
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Nagre-recruitPhase 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Nagre-recruitPhase 2
- University of North Carolina, Chapel Hill · 10 mi ang layo
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Nagre-recruitPhase 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 mi ang layo
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Nagre-recruitPhase 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 mi ang layo
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Nagre-recruitPhase 1
- University of North Carolina, Chapel Hill · 10 mi ang layo
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Nagre-recruitPhase 1
- University of North Carolina, Chapel Hill · 10 mi ang layo
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Nagre-recruitPhase 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mi ang layo
Registry for Adults With Plasma Cell Disorders (PCD's)
Nagre-recruitObservasyonal na pag-aaral
- North Carolina Cancer Hospital, Chapel Hill · 10 mi ang layo
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Nagre-recruitObservasyonal na pag-aaral
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi ang layo
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Duke University Health System (DUHS), Durham
Pag-aaral para sa Multiple Myeloma sa ibang lungsod
- New York City, NY60 pag-aaral
- Boston, MA42 pag-aaral
- Atlanta, GA41 pag-aaral
- Houston, TX38 pag-aaral
- Nashville, TN32 pag-aaral
- Denver, CO26 pag-aaral
- Columbus, OH24 pag-aaral
- Rochester, MN24 pag-aaral
- Baldwin Park, CA23 pag-aaral
- St. Louis, MO23 pag-aaral
- Chicago, IL22 pag-aaral
- Washington, DC22 pag-aaral
Iba pang pag-aaral sa Durham
- Kanser sa Suso63 pag-aaral
- Kanser (lahat ng uri)59 pag-aaral
- Non-Small Cell Lung Cancer39 pag-aaral
- Metastatic Cancer33 pag-aaral
- Acute Myeloid Leukemia33 pag-aaral
- Kanser sa Baga32 pag-aaral
- Kanser sa Prostate32 pag-aaral
- Colorectal Cancer28 pag-aaral
- Kanser sa Ovary27 pag-aaral
- Chronic Lymphocytic Leukemia27 pag-aaral
- Pagkabigo ng Puso26 pag-aaral
- Kanser sa Pancreas25 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.